Publication: BMC Infectious Diseases
Abstract
Carbapenem-resistant Enterobacterales bloodstream infections carry high mortality, and limited access to novel antimicrobials in some regions makes optimizing existing therapies like tigecycline critical. This prospective study conducted in Thailand enrolled patients receiving high-dose tigecycline for carbapenem-resistant Enterobacterales bloodstream infections, collecting serial plasma concentrations to calculate steady-state AUC using Phoenix WinNonlin via non-compartmental analysis. Among 28 patients with pharmacokinetic data, a target of AUCss,0-24h/MIC of at least 9.90 was identified as significantly associated with reduced mortality and improved microbiological eradication, with the causative isolates showing MIC50 and MIC90 values of 0.5 and 1 mg/L, respectively. All-cause mortality remained substantial (50% by day 14), underscoring the severity of these infections despite treatment. The authors propose this exploratory PK/PD target to help guide high-dose tigecycline therapy, particularly against Klebsiella pneumoniae with low MICs.
Author(s): Somsirikarnjanakoon S, Nasomsong W, Hemapanpairoa J, Juntanawiwat P, Santimaleeworagun W
Published: May 20, 2026
Phoenix WinNonlin: PK/PD Targets That Hold Up
Phoenix WinNonlin calculated the steady-state AUC behind this tigecycline PK/PD target, the kind of exposure-response analysis that helps guide therapy in serious infections. Phoenix WinNonlin is the gold standard engine for noncompartmental analysis, PK/PD, and toxicokinetic modeling, part of a Phoenix platform that has trained more than 9,000 people.
